IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells

Journal of Immunology

Volumn 174, Issue 9, 2005, Pages 5261-5269

  Kawauchi, Kiyotaka ^a   Ihjima, Kimiko ^a,b   Yamada, Osamu ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADICICOL; RAPAMYCIN; S6 KINASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 17844380300     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.9.5261     Document Type: Article

References (46)

1. Bearss, D. J., L. H. Hurley, and D. D. Von Hoff. 2000. Telomere maintenance mechanisms as a target for drug development. Oncogene 19:6632.
2. Mergay, J.-L., J.-F. Riou, P. Malliet, M.-P. Tculade-Fichou, and E. Gilson. 2002. Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 30:839.
3. Maida, Y., S. Kyo, T. Kanaya, Z. Wang, N. Yatabe, M. Tanaka, M. Nakamura, M. Ohmichi, N. Gotoh, S. Murakami, and M. Inoue. 2002. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogens 21:4071.
4. Haik, S., L. R. Gauthier, C. Granotier, J. M. Peyrin, C. S. Lages, D. Dormont, and F. D. Boussin. 2000. Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells. Oncogens 19:2957.
5. Tu, W., D.-K. Zhang, P.-T. Cheung, S.-W. Tsao, and Y.-L. Lau. 1999. Effect of insulin-like growth factor 1 on PHA-stimulaled cord blood mononuclear cell telomerase activity. Br. J. Haematol 104:785.
6. Kyo, S., T. Kanaya, M. Takakura, M. Tanaka, and M. Inoue. 1999. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int. J. Cancer 80:60.
7. Forsythe, H. L., J. L. Jarvis, J. W. Turner, L. W. Elmore, and S. E. Holt. 2001. Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J. Biol. Chem. 276:15571.
8. Kang, S. S., T. Kwon, D. Y. Kwon, and S. I. Do. 1999. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274:13085.
9. Lanier, L. L., A. M. Le, C. I. Civin, M. R. Loken, and J. H. Phillips. 1986. The relationship of CD16 (Leu-11) and Leu-19 (HNK-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136:4480.
10. Ellery, J. M., and P. J. Nicholls. 2002. Alternate signaling pathways from the interleukin-2 receptor. Cytokine Growth Factor Rev. 13:27.
11. Nelson, B. H., and D. M. Willerford. 1998. Biology of the interleukin-2 receptor. Adv. Immunol 70:1.
12. Yamada, O., T. Motoji, and H. Mizoguchi. 1996. Up-regulation of telomerase activity in human lymphocytes. Biochim. Biophys. Acta. 1314:260.
13. Hiyama, K., Y. Hirai, S. Kyoizumi, M. Akiyama, E. Hiyama, M. A. Piatyszek, J. W. Shay, S. Ishioka, and M. Yamakido. 1995. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155:3711.
14. Igarashi, H., and N. Sakaguchi. 1996. Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes. Biochem. Biophys. Res. Commun. 219:649.
15. Gong, J. H., G. Maki, and H.G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652.
16. Yamada, O., M. Ichikawa, T. Okamoto, C. Park, T. Moloji, H. Mizoguchi, and A. Shibuya. 2001. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukemia: implications for successful treatment and possible therapeutic strategies. Br. J. Haematol. 113:153.
17. Yamada, O., M. Akiyama, K. Kawauchi, T. Adachi, H. Yamada, H. Kanda, and K. Aikawa. 2003. Overexpression of telomerase confers a survival advantage through suppression of TRF1 gene expression while maintaining differentiation characteristics in K562 cells. Cell Transplant. 12:365.
18. Akiyama, M., O. Asai, Y. Kuraishi, M. Urashima, Y. Hoshi, H. Sakamaki, H. Yabe, T. Furukawa, O. Yamada, H. Mizoguchi, and H. Yamada. 2000. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 25:441.
19. Dignam, J. D., P. L. Martin, B. S. Shastry, and R. G. Roeder. 1983. Eukaryotic gene transcription with purified components. Methods Enzymol. 101:582.
20. bright subset. Blood 97:3146.
21. Kawauchi, K., T. Ogasawara, M. Yasuyama, and S. Ohkawa. 2003. Involvement of Akt kinase in the action of ST1571 on chronic myelogenous leukemia cells. Blood Cells Mol. Dis. 31:11.
22. Bodnar, A. G., N. W. Kim, R. B. Effros, and C. P. Chiu. 1996. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228:58.
23. Weng, N. P., B. L. Levine, C. H. June, and R. J. Hodes. 1996. Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 183:2471.
24. Weng, N. P., B. L. Levine, C. H. June, and R. J. Modes. 1997. Regulation of telomerase RNA template expression in human T lymphocyte development and activation. J. Immunol. 158:3215.
25. Igarashi, H., and N. Sakaguchi. 1997. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood 89:1299.
26. Yu, C. R., J. X. Lin, D. W. Fink, S. Akira, E. T. Bloom, and A. Yamauchi. 1996. Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-α. J. Immunol 157:126.
27. Gesbert, F., C. Gargey, and J. Bertoglio. 1998. Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells. J. Biol. Chem. 273:3986.
28. Wang, K. S., J. Ritz, and D. A. Frank. 1999. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J. Immunol. 162:299.
29. Garcia-Lora, A., S. Pedrinaci, and F. Garrido. 2001. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol. Immunother. 50:191.
30. Garcia-Lora, A., M. Martinez, S. Pedrinaci, and F. Garrido. 2003. Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol. Immunother. 52:59.
31. Yu, T.-K., E. G. Caudell, C. Smid, and E. A. Grimm. 2000. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164:6244.
32. Hatakeyama, M., H. Mori, T. Doi, and T. Taniguchi. 1989. A restricted cytoplasmic region of IL-2 receptor β chain is essential for growth signal transduction but not for ligand binding and internalization. Cell 59:837.
33. Jiang, K., B. Zhong, C. Ritchey, D. L. Gilvary, E. Hong-Geller, S. Wei, and J. Y. Djeu. 2003. Regulation of Akt-dependent cell survival by Syk and Rac. Blood 101:236.
34. Kimura, A., M. Ohmichi, J. Kawagoe, S. Kyo, S. Mabuchi, T. Takahashi, C. Ohshima, E. Arimoto-Ishida, Y. Nishio, M. Inoue, et al. 2004. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 23:4505.
35. Wang, Z., S. Kyo, M. Takakura, M. Tanaka, N. Yatabe, Y. Maida, M. Fujiwara, J. Hayakawa, M. Ohmichi, K. Koike, and M. Inoue. 2000. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 60:5376.
36. Akiyama, M., T. Hideshima, T. Hayashi, Y.-T., Tai, C. S. Mitsiades, N. Mitsiades, D. Chauhan, P. Richardson, N. C. Munshi, and K. C. Anderson. 2002. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62:3876.
37. Liu, K., R. J. Hodes, and N.-p. Weng. 2001. Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol. 166:4826.
38. Shiotsu, Y., S. Soga, and S. Akinaga. 2002. Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex. Leuk. Lymphoma 43:961.
39. Blagosklonny, M. V. 2002. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16:455.
40. Sato, S., N. Fujita, and T. Tsuruo. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97:10832.
41. Castro, A. F., J. F. Rebhun, G. J. Clark, and L. A. Quilliam. 2003. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278:32493.
42. s6k FEBS Lett. 410:78.
43. Allsop, R. C., H. Vaziri, C. Patterson, S. Goldstein, E. V. Younglai, A. B. Futcher, C. W. Greider, and C. B. Harley. 1992. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. USA 89:10114.
44. Yamada, O. 1996. Telomeres and telomerase in human hematologic neoplasia. Int. J. Hematol. 64:87.
45. Tauchi, T., K. Shin-ya, G. Sashida, M. Sumi, A. Nakajima, T. Shimamoto, J. H. Ohyashiki, and K. Ohyashiki. 2003. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22:5338.
46. Dudognon, C., F. Pendino, J. Hillion, A. Saumet, M. Lanotte, and E. Segal-Bendirdjian. 2004. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogens 23:7469.